Active surveillance of adverse events following ChAdOx1 nCoV-19 immunization in geriatric population: a prospective multi-centric study from Jaipur, Rajasthan, India

Active surveillance of adverse events following ChAdOx1 nCoV-19 immunization in geriatric population: a prospective multi-centric study from Jaipur, Rajasthan, India

India launched its coronavirus disease 2019 (COVID-19) vaccination drive starting with healthcare workers. The aim of the study was to evaluate adverse events following immunization (AEFI) amongst the Geriatric population associated with two doses of ChAdOx1 nCoV-19 vaccine. We also evaluated associ...

Full description

Bibliographic Details
Main Authors:	Anil Bhandari, Surya Pratap Singh Tiwari, Monika Rathore, Lokendra Sharma, Smita Jain
Format:	Article
Language:	English
Published:	PAGEPress Publications 2022-01-01
Series:	Geriatric Care
Subjects:	COVID-19 vaccine ChAdOx1nCoV-19 adverse events following immunization.
Online Access:	https://www.pagepressjournals.org/index.php/gc/article/view/9908

Similar Items

Humoral Immunogenicity and Reactogenicity of the Standard ChAdOx1 nCoV-19 Vaccination in Taiwan
by: Jer-Hwa Chang, et al.
Published: (2022-02-01)

LGI-1 encephalopathy following ChAdOx1 nCov-19 vaccination
by: Tamara Garibashvili, et al.
Published: (2022-06-01)

Covid Antibody Titers in Cancer Patients Following Vaccination with ChAdOx1 nCOV-19 Vaccine
by: Ashish Chavan, et al.
Published: (2024-01-01)

Fatal myositis, rhabdomyolysis and compartment syndrome after ChAdOx1 nCoV-19 vaccination
by: Szu-Ting Huang, et al.
Published: (2022-12-01)

Immunogenicity Differences of the ChAdOx1 nCoV-19 Vaccine According to Pre-Existing Adenovirus Immunity
by: Jinnam Kim, et al.
Published: (2023-04-01)

An Immunobridging Study to Evaluate the Neutralizing Antibody Titer in Adults Immunized with Two Doses of Either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901
by: Josue Antonio Estrada, et al.
Published: (2022-04-01)

Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19
by: Jie Wei, et al.
Published: (2023-02-01)

Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults
by: Prasad S. Kulkarni, et al.
Published: (2024-12-01)

Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial [version 2; peer review: 2 approved]
by: Mainga Hamaluba, et al.
Published: (2023-11-01)

Acute Polyserositis with Cardiac Tamponade and Bilateral Refractory Pleural Effusion after ChAdOx1 nCoV-19 Vaccination
by: Guan-Yi Li, et al.
Published: (2022-08-01)

Case report: Early onset Marin-Amat syndrome after receiving ChAdOx1 nCoV-19 vaccination
by: Ping-Feng Tsai, et al.
Published: (2022-11-01)

Immunogenicity of ChAdOx1-nCoV-19 vaccine in solid malignancy patients by treatment regimen versus healthy controls: A prospective, multicenter observational study
by: Nattaya Teeyapun, et al.
Published: (2022-10-01)

Adverse Events Following Immunization Associated with the First and Second Doses of the ChAdOx1 nCoV-19 Vaccine among Healthcare Workers in Korea
by: Minji Jeon, et al.
Published: (2021-09-01)

A Quantitative Benefit–Risk Analysis of ChAdOx1 nCoV-19 Vaccine among People under 60 in Italy
by: Raffaele Palladino, et al.
Published: (2021-06-01)

ChAdOx1 nCoV-19 Immunogenicity and Immunological Response Following COVID-19 Infection in Patients Receiving Maintenance Hemodialysis
by: Wisit Prasithsirikul, et al.
Published: (2022-06-01)

Acute Fulminant Myocarditis After ChAdOx1 nCoV-19 Vaccine: A Case Report and Literature Review
by: Chia-Tung Wu, et al.
Published: (2022-04-01)

Comparison of Antibody Persistence up to 6 Months after Additional Booster Vaccination with ChAdOx1 nCoV-19 Vaccine
by: Pawita Suwanwattana, et al.
Published: (2023-06-01)

Severe but Self-Limiting Polyarthralgia with Functional Impairment Following ChAdOx1 nCov-19 Vaccination in an Elderly Recipient
by: Joel Ern Zher Chan, et al.
Published: (2021-10-01)

Profile of Humoral Immunity and B Cell Pool in Infection with the SARS-CoV-2 Prototype Strain and AZD1222 (ChAdOx nCoV-19) Vaccination
by: Débora Familiar-Macedo, et al.
Published: (2025-01-01)

An autopsy case of cerebral arterial thrombosis after vaccination with ChAdOx1 nCOV-19
by: Hyeji Yang, et al.
Published: (2022-08-01)

ChAdOx1 nCoV-19 Vaccine Side Effects among Healthcare Workers in Trinidad and Tobago
by: Chavin D. Gopaul, et al.
Published: (2022-03-01)

Robust specific RBD responses and neutralizing antibodies after ChAdOx1 nCoV-19 and CoronaVac vaccination in SARS-CoV-2– seropositive individuals
by: Edgar Ruz Fernandes, PhD, et al.
Published: (2023-05-01)

High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events
by: Evangelos Terpos, et al.
Published: (2021-07-01)

Active surveillance of adverse events following coronavirus disease 2019 immunization in the elderly population: A prospective multi-centric study from Jaipur, Rajasthan, India
by: Surya Pratap Singh Tiwari, et al.
Published: (2021-01-01)

The Effects of CoronaVac and ChAdOx1 nCoV-19 in Reducing Severe Illness in Thailand: A Retrospective Cohort Study
by: Thanyarat Promlek, et al.
Published: (2023-01-01)

Immunogenicity of The BNT162b2 COVID-19 mRNA and ChAdOx1 nCoV-19 Vaccines in Patients with Hemoglobinopathies
by: Osman O. Radhwi, et al.
Published: (2022-01-01)

Safety of ChAdOx1 nCoV-19 Vaccine: Independent Evidence from Two EU States
by: Abanoub Riad, et al.
Published: (2021-06-01)

Effectiveness of the chAdOx1 nCoV-19 vaccine in preventing COVID-19 infection
by: Tarana Sarwat, et al.
Published: (2022-01-01)

Effectiveness, safety, and immunogenicity of half dose ChAdOx1 nCoV-19 COVID-19 Vaccine: Viana project
by: Valéria Valim, et al.
Published: (2022-08-01)

Platelet Activation and Cytokine Release of Interleukin-8 and Interferon-Gamma-Induced Protein 10 after ChAdOx1 nCoV-19 Coronavirus Vaccine Injection
by: Chih-Lung Shen, et al.
Published: (2023-02-01)

Myasthenia gravis with ocular symptoms following a ChAdOx1 nCoV-19 vaccination: A case report
by: Min Chae Kang, et al.
Published: (2022-09-01)

Temporal Association between Hampton’s Hump Pulmonary Embolism and First-Dose ChAdOx1 nCov-19 Vaccine in a Patient with Activated Protein C Resistance
by: Gernot Kriegshäuser, et al.
Published: (2022-10-01)

A case of Vaccine-Induced Thrombotic Thrombocytopenia (VITT) with thrombosis of the superior mesenteric artery after ChAdOx1 nCov-19 COVID-19 Vaccine
by: Laura Pini, et al.
Published: (2021-12-01)

Kaposi Sarcoma as a Possible Cutaneous Adverse Effect of ChAdOx1 nCov-19 Vaccine: A Case Report
by: Yan-Han Li, et al.
Published: (2024-10-01)

Superficial venous thrombosisas a possible consequence of ChAdOx1 nCoV-19 vaccine: two case reports
by: Mukesh Kumar Sah, et al.
Published: (2022-05-01)

Sinopharm’s BBIBP-CorV Vaccine and ChAdOx1 nCoV-19 Vaccine Are Associated with a Comparable Immune Response against SARS-CoV-2
by: Ahmed Samir Abdelhafiz, et al.
Published: (2022-09-01)

Protective Immunity of COVID-19 Vaccination with ChAdOx1 nCoV-19 Following Previous SARS-CoV-2 Infection: A Humoral and Cellular Investigation
by: Tamiris Azamor, et al.
Published: (2022-08-01)

Population-wide persistent hemostatic changes after vaccination with ChAdOx1-S
by: Bas de Laat, et al.
Published: (2022-07-01)

Seven-Month Analysis of Five SARS-CoV-2 Antibody Assay Results after ChAdOx1 nCoV-19 Vaccination: Significant Decrease in SARS-CoV-2 Antibody Titer
by: Seri Jeong, et al.
Published: (2021-12-01)

The immunogenicity of the ChAdOx1 nCoV-19 vaccination in participants with underlying comorbidity diseases: A prospective cohort study
by: Thachanun Porntharukchareon, et al.
Published: (2023-08-01)